Tirzepatide and Retatrutide: A Comprehensive Review
Introduction
Tirzepatide and retatrutide are emerging multi-action peptide drugs that have garnered significant attention for their potent effects on weight loss and metabolic control. Tirzepatide (approved under the brand Mounjaro for diabetes) is a dual incretin mimetic, while retatrutide is an investigational triple-agonist. Both are being studied as treatments for obesity and type 2 diabetes mellitus (T2DM), aiming to improve upon the efficacy of existing glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide. This report reviews the latest peer-reviewed research on tirzepatide and retatrutide, focusing on their mechanisms of action, clinical trial outcomes (especially recent data from the past 1–2 years), efficacy in weight loss and metabolic health, safety profiles, regulatory status, and comparisons with semaglutide and other GLP-1 agonists.
Mechanism of Action of Tirzepatide and Retatrutide
Tirzepatide (Dual GIP/GLP-1 Agonist): Tirzepatide is often referred to as a "twincretin" because it combines agonism of two gut incretin hormones: glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors[1][2]. By activating GIP and GLP-1 receptors, tirzepatide enhances insulin secretion and suppresses glucagon in a glucose-dependent manner, much like GLP-1 agonists, but with added effects from GIP signaling (Frias et al., 2021). Notably, GIP receptor activation may synergistically amplify GLP-1's metabolic effects and potentially mitigate some of GLP-1's side effects. Preclinical studies suggest that GIPR activation can reduce GLP-1–induced nausea and vomiting, improving tolerability[3]. Tirzepatide is a 39–amino acid synthetic peptide engineered with a fatty acid moiety to prolong its half-life (~5 days), allowing once-weekly dosing (Frias et al., 2021). In summary, tirzepatide's dual action leads to enhanced glucose-dependent insulin release, glucagon suppression (during hyperglycemia), delayed gastric emptying, and reduced appetite, thereby improving glycemic control and promoting weight loss (Jastreboff et al., 2022[4]).
Retatrutide (Triple GIP/GLP-1/Glucagon Agonist): Retatrutide is a single peptide that acts as an agonist at three receptors: GIP, GLP-1, and the glucagon receptor (GCG) (Sanyal et al., 2024). This triple-hormone agonism represents a novel mechanism aiming to harness the complementary benefits of all three gut hormones. Like tirzepatide, retatrutide stimulates insulin secretion and inhibits gastric emptying via GLP-1 and GIP receptors. In addition, by activating the glucagon receptor, retatrutide can increase energy expenditure and lipolysis. Glucagon receptor stimulation in the liver promotes hepatic fat oxidation and may improve fatty acid metabolism[5]. Indeed, the liver has minimal GLP-1/GIP receptors but is rich in glucagon receptors, suggesting the glucagon agonist component helps reduce liver fat and enhance metabolic rate (Sanyal et al., 2024). Retatrutide's peptide structure and fatty-acid conjugation confer a long half-life (~6 days) for weekly dosing[6][7]. Overall, retatrutide's mechanism combines potent appetite suppression and insulinotropic effects (via GLP-1/GIP) with increased energy expenditure and fat utilization (via glucagon receptor activation), a pharmacologic profile that has yielded unprecedented weight loss in early trials (Jastreboff et al., 2023).
Clinical Trial Outcomes and Latest Data
Tirzepatide: Key Clinical Trials
Tirzepatide has been evaluated in multiple Phase 3 trials, primarily the SURPASS series for type 2 diabetes and the SURMOUNT trials for obesity. In patients with T2DM, tirzepatide demonstrated remarkable glycemic efficacy and weight reduction. For example, the SURPASS-2 trial (Frías et al., 2021) compared tirzepatide to semaglutide in adults with T2DM inadequately controlled on metformin. Tirzepatide (5, 10, and 15 mg weekly) achieved HbA<sub>1c</sub> reductions of roughly 2.0%–2.3%, significantly greater than the ~1.8% reduction with semaglutide 1 mg[4]. Tirzepatide also induced superior weight loss: by 40 weeks, patients on tirzepatide 15 mg lost on average 11.0 kg more body weight than baseline, versus about 5.5 kg with semaglutide (an incremental ~5.5 kg advantage)[8]. All doses of tirzepatide were statistically superior to semaglutide for both A1c and weight endpoints (Frías et al., 2021). These findings established tirzepatide's efficacy in diabetes management, with a substantial proportion of patients reaching glycemic targets (HbA<sub>1c</sub> <7% or even <5.7%) and losing clinically meaningful weight.